BioCryst to sell European Orladeyo business for up to $264M

Adam Webb/iStock via Getty Images

BioCryst Pharmaceuticals (NASDAQ:BCRX) on Friday announced an agreement to sell European business related to its bestselling therapy Orladeyo to Neopharmed Gentili, an Italian pharmaceutical company, for up to $264M.

The deal comes after the treatment indicated for a rare genetic